Table 5 Characteristics of esophageal carcinoma patients with or without hypothyroidism/levothyroxine
Hypothyroidism/Levothyroxine | P 1 | |||
|---|---|---|---|---|
Variables | No | Yes | ||
Sex | Female | 148(13.8%) | 34(33.3%) | <0.01 |
Male | 924(86.2%) | 68(66.7%) | ||
Race | non-White | 131(12.2%) | 15(14.7%) | 0.44 |
White | 941(87.8%) | 87(85.3%) | ||
BMI | ≤25 | 262(29.1%) | 23(25.8%) | 0.62 |
>25 | 638(70.9%) | 66(74.2%) | ||
Age (years) | ≤64 | 569(53.1%) | 44(43.1%) | 0.06 |
>64 | 503(46.9%) | 58(56.9%) | ||
Heavy alcohol use history | No | 839(78.4%) | 83(81.4%) | 0.53 |
Yes | 231(21.6%) | 19(18.6%) | ||
Smoke at diagnosis | No | 830(77.6%) | 92(91.1%) | <0.01 |
Yes | 239(22.4%) | 9(8.9%) | ||
KPS | ≤70 | 104(9.7%) | 13(12.7%) | 0.30 |
>70 | 968(90.3%) | 89(87.3%) | ||
AF | No | 1013(94.5%) | 98(96.1%) | 0.65 |
Yes | 59(5.5%) | 4(3.9%) | ||
Tumor histology | ADC | 841(79.9%) | 73(71.6%) | 0.05 |
SCC | 211(20.1%) | 29(28.4%) | ||
Tumor location | Upper/middle | 140(13.1%) | 19(18.6%) | 0.13 |
Low | 932(86.9%) | 83(81.4%) | ||
Tumor differentiation | Well/moderate | 477(45.0%) | 40(39.6%) | 0.35 |
Poor | 583(55.0%) | 61(60.4%) | ||
Tumor length (cm) | ≤5 | 537(56.9%) | 62(66.7%) | 0.08 |
>5 | 407(43.1%) | 31(33.3%) | ||
Clinical stage | I-II | 383(36.6%) | 48(48.5%) | 0.02 |
III-IV | 664(63.4%) | 51(51.5%) | ||
Surgery | No | 553(51.6%) | 64(59.8%) | 0.12 |
Yes | 519(48.4%) | 41(40.2%) | ||
Radiation modality | 3DCRT | 430(40.1%) | 39(38.2%) | 0.75 |
IMRT/proton | 642(59.9%) | 63(61.8%) | ||
Induction chemotherapy | No | 638(59.5%) | 68(66.7%) | 0.17 |
Yes | 434(40.5%) | 34(33.3%) | ||
CRT complete response | No | 651(63.5%) | 54(58.1%) | 0.31 |
Yes | 374(36.5%) | 39(41.9%) | ||
Chemotherapy after relapse | No | 914(85.3%) | 90(88.2%) | 0.47 |
Yes | 158(14.7%) | 12(11.8%) | ||
Local/regional failure rate | No | 290(31.0%) | 25(26.9%) | 0.48 |
Yes | 644(69.0%) | 68(73.1%) | ||
Distant failure rate | No | 532(55.0%) | 62(64.6%) | 0.08 |
Yes | 436(45.0%) | 34(35.4%) | ||